Madrigal Pharmaceuticals price target lowered to $347 from $383 at KeyBanc

KeyBanc lowered the firm’s price target on Madrigal Pharmaceuticals to $347 from $383 and keeps an Overweight rating on the shares. The firm thinks resmetirom’s approval and a higher-than-expected price will drive shares substantially higher as current levels reflect a modest peak sales opportunity for the first NASH therapeutic, the analyst tells investors in a research note.